Ir.celgene.com

Ir Celgene. The Investor Relations website contains information about Celgene Corporation business for stockholders, potential investors, and financial...

Never miss Ir.celgene.com updates: Start reading the news feed of Ir Celgene right away! This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Ir.celgene.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Ir Celgene

Subscribe to related news

New Market Research Report: Celgene Corporation (CELG) – Financial and Strategic SWOT Analysis Review
via military-technologies

2015-04-26 15:07:50 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company...
Celgene Price Target Increased to $80.00 by Analysts at Jefferies Group (CELG)
via americanbankingnews

Investment analysts at Jefferies Group lifted their target price on shares of Celgene (NASDAQ: CELG) from $75.00 to $80.00 in a note issued to investors on Friday. The analysts wrote, “CELG beat 2Q estimates for Revlimid sales and increased 2...
Is it the Best Time to Buy Celgene Corp (NASDAQ:CELG)?
via streetreport

[Market Realist] Celgene Corp (NASDAQ:CELG)(TREND ANALYSIS) will announce its 3Q15 earnings result for the period ending September 30, 2015, Wall Street has estimated Celgene’s 3Q15 revenues to be about $2.4 billion, a strong growth of about 21.2% on...
Mid Day Movers: ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC), Celgene Corporation(NASDAQ:CELG), Zalicus Inc(NASDAQ:ZLCS...
via usmarketbuzz

ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC) shares added 2.12% to $1.01. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as...
Celgene Corporation (NASDAQ:CELG) in Spotlight
via marketswired

[Business Wire] Celgene Corporation (NASDAQ:CELG)(TREND ANALYSIS) announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (mongersen) in patients with active Crohn’s disease were published...

Ir.celgene.com popular pages

Bristol Myers Squibb: Investor Relations

Find information and tools for investors, stockholders and financial analysts, including share and dividend information, acquisition-related information, latest news and corporate reporting.
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated

Oral REVLIMID is approved for treatment until disease progression BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary o...

Press Release Archive | Celgene Corporation

The Investor Relations website contains information about Celgene Corporation business for stockholders, potential investors, and financial analysts.